Colorectal Cancer

Patients with metastatic colorectal cancer now have more treatment options than ever, explains Tanios Bekaii-Saab, M.D.

The National LGBT Cancer Network is making cancer screenings more available to a high-risk, underserved population.

In colorectal and other cancers, financial burden is worsened by expensive drugs, long-term treatment and sharing of insurance costs.

While colorectal cancer on the left side may have a survival benefit, the stage of the cancer may pay an important role.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for Hispanic men, rates have remained essentially unchanged. A new study suggests that lower rates of screening may be the driver of this disparity.

Volker Heinemann says early tumor shrinkage may be a better predictor than progression-free survival in colorectal cancer.

CURE spoke with Axel Grothey about advances in the treatment of colorectal cancer.

A wide-range of colon cancer screening options will be available and insured for patients, thanks to recent USPSTF recommendations.

The combination of Opdivo and Yervoy showed promise for certain patients with colorectal cancer in a phase 2 study.

While inherited factors do play a role in many people getting colorectal cancer, researchers are still unsure how to identify these mutations.

Patients' confidence that they can manage problems related to their colorectal cancer can have a great impact on their recovery, according to a recent study.

The location of colon cancer may have a say in survival, according to a recent analysis.

Since chemotherapy can offer only a limited amount of help in fighting gastroesophageal cancers, a growing emphasis on prevention — as well as on the development of immunotherapies — will be extremely important.

In the midst of the approval of new treatments for colorectal cancer, Alan P. Venook wants to remind health care professionals not to forget the more traditional and established therapies.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

David Dubin, founder, AliveAndKickn, provides advice for Lynch syndrome previvors.

While many advocacy groups concentrate their efforts on raising awareness or finding a cure for cancer, PCF has always had its focus squarely on prevention and patient education.